Prelude Therapeutics (PRLD)
1.04
0.02 (1.96%)
At close: Jan 15, 2025, 2:33 PM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | -121.83M | -115.44M | -111.69M | -56.93M | -27.57M | -14.68M |
| Depreciation & Amortization | 1.17M | 1.32M | 915.00K | 542.00K | 382.00K | 149.00K |
| Stock-Based Compensation | 25.62M | 25.14M | 20.93M | 5.58M | 846.00K | 180.00K |
| Other Working Capital | -8.21M | 1.28M | -278.00K | 3.46M | 121.00K | 661.00K |
| Other Non-Cash Items | -1.54M | 4.31M | 1.33M | 11.00K | 10.00K | 15.00K |
| Deferred Income Tax | n/a | n/a | 1.36M | n/a | n/a | n/a |
| Change in Working Capital | -10.48M | 932.00K | 3.63M | 4.62M | 667.00K | 1.38M |
| Operating Cash Flow | -107.06M | -83.73M | -83.53M | -46.18M | -25.66M | -12.95M |
| Capital Expenditures | -3.51M | -3.02M | -2.32M | -621.00K | -780.00K | -529.00K |
| Acquisitions | n/a | -84.71K | n/a | n/a | n/a | n/a |
| Purchase of Investments | -221.63M | -119.22M | -261.48M | n/a | n/a | n/a |
| Sales Maturities Of Investments | 190.50M | 203.93M | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | n/a | 84.71K | -261.48K | n/a | n/a | n/a |
| Investing Cash Flow | -34.65M | 81.69M | -263.80M | -621.00K | -780.00K | -529.00K |
| Debt Repayment | n/a | n/a | n/a | -258.00K | -124.00K | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 1.34M | 815.00K | 3.47M | 79.86M | 29.85M | 17.94M |
| Financial Cash Flow | 136.40M | 815.00K | 164.90M | 246.23M | 29.73M | 17.94M |
| Net Cash Flow | -5.31M | -1.22M | -182.44M | 199.43M | 3.28M | 4.45M |
| Free Cash Flow | -110.58M | -86.75M | -85.85M | -46.80M | -26.45M | -13.48M |